Disc Medicine vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Disc Medicine is a Nasdaq-listed clinical-stage biopharma focused on hematologic diseases including polycythemia vera and myelofibrosis; lead asset bitercept targets heme biosynthesis and iron homeostasis;
About
Disc Medicine is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Watertown, Massachusetts, focused on developing novel therapies for serious hematologic disorders. The company's scientific foundation lies in understanding red blood cell biology — specifically heme biosynthesis (the process by which cells produce heme, the oxygen-carrying component of hemoglobin) and iron homeostasis (how the body regulates iron). By targeting these pathways, Disc Medicine aims to address diseases where current treatments are inadequate, including polycythemia vera (PV), myelofibrosis, and other bone marrow-driven blood disorders.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Disc Medicine vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.